Chosa Oncology AB

Equities

CHOSA

SE0007784319

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 23:00:00 31/01/2024 GMT			5-day change	1st Jan Change
0.53 ^SEK	+51.43%		-.--%	-6.03%

04-30	Chosa Oncology AB Announces Resignation of Lars Hedbys as Chairman	CI
03-28	Chosa Oncology Names CFO, Chief Commercial Officer	MT

Chosa Oncology AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 29, 2024 at 08:16 am

Chosa Oncology AB reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was SEK 2.82 million compared to SEK 0.932 million a year ago. Basic loss per share from continuing operations was SEK 0.04 compared to SEK 0.11 a year ago.
For the full year, net loss was SEK 23.94 million.

Latest news about Chosa Oncology AB

Chosa Oncology AB Announces Resignation of Lars Hedbys as Chairman	04-30	CI
Chosa Oncology Names CFO, Chief Commercial Officer	03-28	MT
CHOSA Oncology AB Announces Chief Financial Officer Changes	03-28	CI
CHOSA Oncology Appoints Claus Frisenberg Pedersen as Chief Commercial Officer	03-28	CI
Chosa Oncology AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-29	CI
Chosa Oncology AB Postpones Publication of Interim Report for the Second Quarter of 2023	27/08/23	CI
CHOSA Oncology AB Publishes Results from Clinical Phase 2 Trial of Liposomal Formulation in Breast Cancer, Using Predictive Marker for Cisplatin	03/06/23	CI
Chosa Oncology AB Announces Board Changes	26/05/23	CI
CHOSA Oncology AB Presents Clinical Phase 2 Results of LiPlaCis and its Drug Response Predictor Test at ASCO 2023	25/05/23	CI
RhoVac AB will Change its Name to CHOSA Oncology AB	15/02/23	CI
RhoVac AB has Changed its Name to CHOSA Oncology AB	10/02/23	CI
Rhovac AB Announces CEO Changes	18/01/23	CI
RhoVac AB Announces Board Changes	18/01/23	CI
Chosa ApS completed the acquisition of RhoVac AB from M2 Asset Management AB and others in a reverse merger transaction.	17/01/23	CI
Chosa ApS entered into an agreement to acquire RhoVac AB from M2 Asset Management AB and others in a reverse merger transaction for SEK 30.4 million.	04/12/22	CI
RhoVac AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/11/22	CI
RhoVac AB Announces Resignation of Anders Ljungqvist as Board Member	18/10/22	CI
RhoVac AB Appoints Lars Hedbys as Acting CEO, Starting from September 1, 2022	26/08/22	CI
RhoVac AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	26/08/22	CI
Rhovac AB Announces Resignation of Anders Månsson as CEO	15/07/22	CI
RhoVac AB's Phase IIb Study in Prostate Cancer , BRaVac, Failed to Meet Its Primary Endpoint	30/05/22	CI
Pre-Clinical Findings Support the Potential Use of RhoVac AB's Drug Candidate, Onilcamotide, Across Several Cancers	18/05/22	CI
RhoVac AB Reports Earnings Results for the First Quarter Ended March 31, 2022	05/05/22	CI
RhoVac AB Announces Scientific Publication Supports its Cancer Treatment Method	01/03/22	CI
RhoVac AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	11/02/22	CI

Chart Chosa Oncology AB

Duration

Period

More charts

Company Profile

Chosa Oncology AB, formerly RhoVac AB, is a Sweden-based biotechnology company. The Company specializes on research and development of immunotherapeutic drugs. The Company's business focus is found in the development of vaccines for the treatment of metastatic cancer. Immunotherapy treatment is an important part of the operation where the body's own immune system is used to fight and eliminate cancer cells. The Company's drug candidate is used in combination with surgery or radiotherapy. Its products are iCIP, which is combines the identification of patients that will benefit from cisplatin treatment with the ability to treat them with higher efficacy and less toxicity; LiPlaCis is a liposomal formulation of cisplatin enabling direct delivery of this known agent to tumor sites; and DRP is a multigene mRNA-based Drug-specific Response Predictor built upon a deep systems biology analysis of all transcriptional (RNA) changes in tumor cells in response to a broad range of drug types.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CHOSA ONCOLOGY AB	-6.03%	3.55M
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
REGENERON PHARMACEUTICALS, INC.	+23.21%	117B
ARGENX SE	+25.15%	27.67B
BIONTECH SE	-20.17%	20.33B
GENMAB A/S	-17.12%	16.79B
BEIGENE, LTD.	-18.07%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B

Bio Therapeutic Drugs